Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
about
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapyMultimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the LiteratureUK guidelines for the management of bone sarcomasManagement of Ewing sarcoma family of tumors: Current scenario and unmet needCharacterization and drug resistance patterns of Ewing's sarcoma family tumor cell linesPatterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma CommitteeInterval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas.Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.Treatment pathway of bone sarcoma in children, adolescents, and young adultsPaley's multiplier method does not accurately predict adult height in children with bone sarcoma.Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.Chemotherapy in Ewing's sarcoma.Pre-chemotherapy preservation of fertility in male patients with high-grade malignant bone and soft tissue tumors.Do patients with ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity?Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults.Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcomaMetastatic Ewing's sarcoma/PNET of kidney in 40 year old patientPhyseal distraction for joint preservation in malignant metaphyseal bone tumors in childrenEn bloc spondylectomy in malignant tumors of the spine.Askin's tumor: a case report and literature review.The clinical outcomes of extracorporeal irradiated and re-implanted cemented autologous bone graft of femoral diaphysis after tumour resection.Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology GroupOutpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.Pharmacotherapy of sarcoma.What Sport Activity Levels Are Achieved in Patients After Resection and Endoprosthetic Reconstruction for a Proximal Femur Bone Sarcoma?Sarcomas gone bad: what to do about recurrent Ewing sarcoma.Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome.Ewing sarcoma: clinical state-of-the-art.Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.The treatment outcome for adult patients with Ewing's sarcoma.The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.Management and Outcome of Ewing Sarcoma of the Head and Neck.Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).Survival of adolescents with cancer treated at pediatric versus adult oncology treatment centers in France.Outcomes after interdisciplinary management of 7 patients with Askin tumor.Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial.
P2860
Q24186965-1C585B34-F56B-4105-82F7-95FAFC147ADDQ26740437-100F6287-BD77-4FB0-8B03-57691D4013B6Q26752425-4B4F30A0-E236-4421-A8AD-ED62A4202754Q28073218-83D8870D-CB72-4880-A49E-49B7A264A177Q28535586-030020EB-3F07-4102-9826-425402722C5CQ33396263-43442608-32B8-41F8-B150-06FB6314720FQ33403469-2749B5A6-F8E3-4651-ABB7-C27604FE41FFQ33410703-E10BB4D4-8346-410B-A5FC-45B7FD4E9676Q33835657-9F87324C-EB1F-4BCA-BC84-E2A9EB2E400AQ33839052-BFD8DE15-9DED-438E-B208-9A00B8EFD35DQ34155816-5809C5B8-23F2-49B1-91BA-BCD9CCF68263Q34164686-83BE2560-1787-46C8-8B42-1C585A5AD64CQ34265818-1A193D7E-D65F-423F-A9B7-8C7944282D01Q35050301-AED57AC3-AC0D-4F63-92D0-A88B9BD1CFACQ35131440-00707175-35C5-4808-92E2-49E813A5C669Q35179978-D8554A92-63FD-476E-AA35-D40362B3BA8EQ35848369-72C631E7-B649-4D6C-9E6B-AB563100CCB0Q35884342-A0B473C9-57C7-4EB7-AFEE-E7176A84CFA8Q35946703-72DA0495-EA5A-4FE2-85CA-76E8BE3E02DCQ36542645-403E17C0-CA5B-42BF-A9FE-FF3DC9BEC2E1Q36565249-399030F1-24B7-4944-A437-1792BD4895A9Q36721999-61485A75-144E-42DC-B225-A391E6D73FC1Q36881113-F39881BE-47E7-41C5-A203-63052BB67F40Q37038352-FDD778FE-617B-4D00-9EEA-8DF008FD3F4FQ37400113-9BF52A25-D137-4C22-A08C-B07EF7FE7FB4Q37532566-1C8636E6-47DA-4664-9CBC-ED8BE09FF9F3Q37621255-7421E66B-B4A0-40F7-89D6-367EE21C7009Q37890995-3E37806C-7A00-4B3F-A728-EA71256E5366Q37958019-AE9D62FD-542D-416A-BE51-AF673CE37D76Q37980482-2757E356-1550-4A4E-AAD3-D3316ADE20AEQ38079197-F5DF1286-2A43-4DB5-ADCF-8DD24BD8E063Q38100720-F81DCDC8-587F-42CE-B463-4EE42F1E3E65Q38315670-FBE02959-E4AB-4867-9909-637EEF393F9DQ38678098-1E04F110-5899-4F6C-A400-6531A7D5D152Q38678925-AAC92628-694E-46AC-A9F7-2D9BD7BD7D79Q39006166-5587A2C3-D7D8-4AE7-A5EC-845D464E174EQ39176628-1E9D80F4-00E0-43A9-949B-DEBD7FC78F7DQ40091463-6DC1574E-32D3-4926-8B6E-9DC84BDB43B1Q40650204-8166DB94-1FFC-4C7C-A156-E3DEA5228477Q40806118-713A9993-B300-4980-8DB1-932A4850DCEC
P2860
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@ast
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@en
type
label
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@ast
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@en
prefLabel
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@ast
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@en
P2093
P356
P1476
Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.
@en
P2093
Alan Craft
Andreas Zoubek
Christine Juergens
Claire Weston
Herbert Juergens
Jean Michon
Jeremy Whelan
Michael Paulussen
Odile Oberlin
P356
10.1002/PBC.20820
P577
2006-07-01T00:00:00Z